主页 > 医学前沿 >
【drug-news】研究发现基因变异会影响阿司匹林预
Genetic variation impacts aspirin's effectiveness in preventing colon cancer, Dartmouth study finds
Dartmouth College Office of Public Affairs • Press Release
Posted 10/24/06 • Susan Knapp • (603) 646-3661
Elizabeth Barry, Research Assistant Professor of Community and Family Medicine (Photo courtesy of Barry)
Dartmouth researchers are among a team of doctors that have learned more about how people may or may not benefit from taking aspirin in the effort to curb colon cancer. Their study, which appears in the Oct. 18 issue of the Journal of the National Cancer Institute, finds that the beneficial effect of aspirin may be limited to individuals who have a specific genetic variation in their ODC gene.
"There is evidence that aspirin and related anti-inflammatory drugs can reduce the risk of colorectal adenomas [polyps] and cancer," says Elizabeth Barry, a research assistant professor of community and family medicine at Dartmouth Medical School, and one the authors of the study. "And with this study, we looked closer at the impact of aspirin in people who have a higher risk of developing colorectal adenomas, which lead to cancer, by examining their ODC genotype. So now we know that aspirin appears to work better in people who have this slight genetic variation, and this finding could potentially be clinically useful in the future by allowing physicians to predict which individuals are likely to benefit from aspirin use for colorectal cancer chemoprevention."
The researchers studied 973 subjects over three years as part of the Aspirin/Folate Polyp Prevention Study. In a randomized manner, some were given aspirin and some were given placebos. Almost half of the participants carried one or two copies of the ODC genetic variation. The study found that there was no association between carrying the genetic variation and the occurrence or new adenomas, but the genotype did influence the effect of aspirin on adenoma development. Those with the ODC genetic variation were 23 percent less likely to develop new adenomas and 49 percent less likely to develop more advanced lesions, which also lead to cancer.
Other authors on the paper include John A. Baron and Maria V. Grau, with Dartmouth Medical School; Shubha Bhat and Thomas G. O'Brien, with the Institute for Medical Research in Wynnewood, Penn.; Carol A. Burke, with the Cleveland Clinic Foundation; Robert S. Sandler, with the University of North Carolina; Dennis J. Ahnen, with the University of Colorado Health Sciences Center in Denver; and Robert W. Haile, with the University of Southern California, Los Angeles.
This study was funded by the National Cancer Institute. 认领认领 Genetic variation impacts aspirin's effectiveness in preventing colon cancer, Dartmouth study finds
研究发现基因变异会影响阿司匹林预防结肠癌疗效
Dartmouth College Office of Public Affairs • Press Release
Posted 10/24/06 • Susan Knapp • (603) 646-3661
达特茅斯学院公共事务办公室•新闻发布
2006/10/24• Susan Knapp • (603) 646-3661
Dartmouth researchers are among a team of doctors that have learned more about how people may or may not benefit from taking aspirin in the effort to curb colon cancer. Their study, which appears in the Oct. 18 issue of the Journal of the National Cancer Institute, finds that the beneficial effect of aspirin may be limited to individuals who have a specific genetic variation in their ODC gene.
为了了解更多关于阿司匹林用于控制结肠癌能否获得很好的疗效，达特茅斯的研究员加入到医生队伍中进行了这项研究。该研究发表在10月18日美国国家癌症研究所发表的杂志上，研究表明对于ODC(鸟氨酸脱羧酶)基因发生了明显遗传变异的患者阿司匹林的预防效果可能是有限的。
"There is evidence that aspirin and related anti-inflammatory drugs can reduce the risk of colorectal adenomas [polyps] and cancer," says Elizabeth Barry, a research assistant professor of community and family medicine at Dartmouth Medical School, and one the authors of the study. "And with this study, we looked closer at the impact of aspirin in people who have a higher risk of developing colorectal adenomas, which lead to cancer, by examining their ODC genotype. So now we know that aspirin appears to work better in people who have this slight genetic variation, and this finding could potentially be clinically useful in the future by allowing physicians to predict which individuals are likely to benefit from aspirin use for colorectal cancer chemoprevention."
“阿司匹林及同类的抗炎药物可以降低直肠结肠腺瘤（息肉）及癌症的危险性，”研究者 Elizabeth Barry（本研究的作者之一，达特茅斯学院社区家庭医学助教）说，“通过检测ODC基因的种类，我们更进一步的观察了阿司匹林治疗直肠结肠腺瘤恶化导致癌症的疗效。结果我们了解到对于基因有该种轻微变异的患者，阿司匹林表现出更好的疗效，这项研究将在未来临床治疗中有很大帮助，在医生的指导下，病人应用阿司匹林作为直肠结肠癌的化学预防
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-08-13 17:14
医学,生命科学网